Literature DB >> 22534272

Evaluation and treatment of the suicidal patient.

David Norris1, Molly S Clark.   

Abstract

Evaluation and treatment of a suicidal patient are challenging tasks for the physician. Because no validated predictive tools exist, clinical judgment guides the decision-making process. Although there is insufficient evidence to support routine screening, evidence shows that asking high-risk patients about suicidal intent leads to better outcomes and does not increase the risk of suicide. Important elements of the history that permit evaluation of the seriousness of suicidal ideation include the intent, plan, and means; the availability of social support; previous suicide attempts; and the presence of comorbid psychiatric illness or substance abuse. After intent has been established, inpatient and outpatient management should include ensuring patient safety and medical stabilization; activating support networks; and initiating therapy for psychiatric diseases. Care plans for patients with chronic suicidal ideation include these same steps, as well as referral for specialty care. In the event of a completed suicide, physicians should provide support for family members who may be experiencing grief complicated by guilt, while also activating their own support networks and risk management systems.

Entities:  

Mesh:

Year:  2012        PMID: 22534272

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  3 in total

Review 1.  Addressing suicidality in primary care settings.

Authors:  J Michael Bostwick; Sandra Rackley
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

2.  Why are suicide rates climbing after years of decline?

Authors:  Nancy Valko
Journal:  Linacre Q       Date:  2017-05-03

3.  Neurexin 1 variants as risk factors for suicide death.

Authors:  Nancy William; Carsten Reissner; Robert Sargent; Todd M Darlington; Emily DiBlasi; Qingqin S Li; Brooks Keeshin; William B Callor; Elliott Ferris; Leslie Jerominski; Ken R Smith; Erik D Christensen; Douglas M Gray; Nicola J Camp; Markus Missler; Megan E Williams; Hilary Coon
Journal:  Mol Psychiatry       Date:  2021-06-25       Impact factor: 15.992

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.